GitLab, Inc. GTLB released its first-quarter results after Tuesday's closing bell. Here's a look at the details in the report. The Details: GitLab reported quarterly earnings of 17 cents per share, which beat the analyst consensus estimate of 15 cents. Quarterly revenue came in at $214.51 million, which beat the Street estimate of $213.16 million.Read Next: These Are The 3 Hottest Stock Market Themes Trending NowFor the first quarter of fiscal 2026, GitLab reported:Customers with more than $5,000 of ARR rea ...

Core Viewpoint - Outlook Therapeutics has received acceptance from the Scottish Medicines Consortium (SMC) for LYTENAVA™ (bevacizumab gamma) to be used in NHS Scotland for treating wet age-related macular degeneration (wet AMD), marking a significant milestone for the company and enhancing treatment options for patients in Scotland [1][2]. Company Overview - Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) to improve the standard of care for retinal diseases [7]. - LYTENAVA™ is the first licensed ophthalmic formulation of bevacizumab for treating wet AMD in the UK, with an initial 10 years of market exclusivity from the date of marketing authorization [1][4]. Clinical Development - The SMC recommendation was based on results from the company's clinical program for ONS-5010/LYTENAVA™, which includes three completed registration clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE [2]. - The product is currently commercially available in the UK for wet AMD treatment [2]. Strategic Collaborations - Outlook Therapeutics has formed a strategic collaboration with Cencora (formerly AmerisourceBergen) to support the global commercial launch of LYTENAVA™ following regulatory approvals, aiming for efficient distribution and market access [3]. Regulatory Status - LYTENAVA™ has received centralized Marketing Authorization from the European Commission and the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for treating wet AMD [4]. - In the United States, ONS-5010/LYTENAVA™ is still investigational, with a Biologics License Application (BLA) resubmitted to the FDA [8].

PHILADELPHIA, June 9, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Civitas Resources, Inc. ("Civitas" or the "Company") (NYSE: CIVI) on behalf of purchasers of Civitas securities between February 27, 2024 through February 24, 2025, inclusive (the "Class Period").Investor Deadline: Investors who purchased or acquired Civitas securities during the Class Period may, no later than JULY 1, 2025, seek to be appointed as a lead plaintiff re ...

Reaffirms Fiscal 2025 Net Sales and Earnings Outlook*SAN DIEGO, June 5, 2025 /PRNewswire/ -- Petco Health and Wellness Company, Inc. (Nasdaq: WOOF) today announced its first quarter 2025 financial results.Q1 2025 Overview Net sales of $1.5 billion decreased 2.3% year over year in line with the company's first quarter outlook Comparable sales decreased 1.3% year over year Gross profit margin expanded approximately 30 basis points to 38.2% as a percentage of net sales Operating Income improved $33.1 million t ...

2025 has hit the halfway point. Our Market Sense experts take a look back while discussing what might be in store for the rest of the year. Fidelity Brokerage Services LLC, Member NYSE, SIPC, 900 Salem Street, Smithfield, RI 02917 1209004.1.0 ...

Core Insights - Business owners exhibit a positive outlook for economic growth in the latter half of 2025, despite mixed feelings regarding the impact of tariffs on the economy [2][6] - The survey indicates that businesses are strategically responding to economic uncertainty by managing inventory carefully and delaying capital expenditures [3][4] Economic Sentiment - Over 60% of business owners believe the economy will grow in the next six months, yet over 55% express dissatisfaction with current tariff policies, viewing them as detrimental to the U.S. economy [6] - More than 70% of respondents are concerned about the impact of tariffs on their businesses, although the immediate effects have been minimal, with over 80% reporting "somewhat of an impact" or "none" [6] Tariff Impact and Business Strategies - A significant portion of business owners anticipates that tariffs will decrease their revenue, with over half believing tariffs will negatively affect their businesses [6] - Approximately 32.55% of businesses have adjusted their inventory levels in response to tariffs, while 31.69% are still evaluating their inventory strategies [6] - Just under 30% of businesses plan to halt hiring, while nearly 50% report no changes to their hiring plans [6] Capital Expenditures and Pricing Strategies - A slight majority (41.68%) of respondents plan to delay major capital expenditures due to economic uncertainty [6] - Over 37% of businesses expect to pass the cost of tariffs onto customers, while just under 30% anticipate absorbing these costs [6]

Core Viewpoint - Outlook Therapeutics has launched LYTENAVA™ (bevacizumab gamma) for the treatment of wet age-related macular degeneration (wet AMD) in Germany and the UK, marking a significant milestone as it is the first and only authorized ophthalmic formulation of bevacizumab for this condition in the European Union and UK [1][5][9] Company Overview - Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing ONS-5010/LYTENAVA™ to enhance the standard of care for retinal diseases [8] - The company has received centralized Marketing Authorization from the European Commission and the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for LYTENAVA™ [5][8] Product Launch and Market Strategy - The commercial launch of LYTENAVA™ in Germany and the UK is supported by a strategic collaboration with Cencora to facilitate market access and distribution [4] - The company aims to ensure success in these markets and is preparing for additional launches across Europe later in 2025 and throughout 2026 [2] Market Context - Off-label repackaged bevacizumab is widely used in Europe and the US, with approximately 2.8 million injections annually in Europe and 2.7 million in the US for retinal diseases [3] - LYTENAVA™ has the potential to mitigate risks associated with the current off-label use of repackaged bevacizumab [3] Regulatory Status - In the United States, ONS-5010/LYTENAVA™ is currently investigational, and a Biologics License Application (BLA) has been resubmitted to the FDA [6][8] - In certain EU member states, ONS-5010/LYTENAVA™ must receive pricing and reimbursement approval before it can be sold [6]

Core Insights - NetApp, Inc. (NTAP) reported fourth-quarter fiscal 2025 non-GAAP earnings of $1.93 per share, exceeding the Zacks Consensus Estimate by 1.6% and reflecting a year-over-year increase of 7.2% [1] - Revenues for the quarter reached $1.73 billion, a 3.8% year-over-year increase, and also surpassed the consensus mark by 0.2% [2] - Management provided a mixed outlook for fiscal 2026, citing global macroeconomic slowdown and increased spending caution [3][4] Financial Performance - Fiscal 2025 revenues rose 5% year over year to $6.57 billion, with non-GAAP earnings per share increasing by 12.4% to $7.25 [2] - The Hybrid Cloud segment generated $1.57 billion in revenue, up 3% year over year, while the Public Cloud segment saw an 8% increase to $164 million [6][8] - Non-GAAP gross margin for the quarter was 69.5%, down 200 basis points from the previous year, while operating income rose 5.8% to $496 million [12] Guidance and Outlook - For fiscal 2026, NTAP expects revenues between $6.625 billion and $6.875 billion, representing a 3% year-over-year increase at the midpoint [4] - Non-GAAP earnings per share are projected to be between $7.60 and $7.90, with gross margin anticipated to be 71-72% [4] Shareholder Returns - In the fiscal fourth quarter, NTAP returned $355 million to shareholders through dividends and share repurchases, with a total of $1.57 billion returned in fiscal 2025 [15][16] - The company announced a dividend of 52 cents per share, payable on July 23, 2025 [16] Market Reaction - Following the earnings announcement, NTAP's shares fell 4.8% in pre-market trading, despite a 10.6% increase over the past month [5]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced news journalists who produce independent content across various financial markets [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content includes insights across sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Shares of Dell Technologies rose on Thursday in extended trading after the company raised its full-year earnings forecast and issued a stronger-than-expected forecast for the current quarter.However, Dell's adjusted earnings per share came up short versus LSEG estimates on in-line revenue.Here's how the computer maker did versus LSEG consensus estimates:Earnings per share: $1.55 adjusted vs. $1.69 estimatedRevenue: $23.38 billion vs. $23.14 billion estimatedDell said it expects $2.25 in adjusted earnings pe ...